Codexis opens first Asian research facility
US biotech company Codexis has opened its first research facility in Asia. Codexis Laboratories Singapore (CLS) is an expansion of the company's r&d operations in the US and Europe and will support the company's pharmaceuticals business in both the innovator and generics markets.
US biotech company Codexis has opened its first research facility in Asia. Codexis Laboratories Singapore (CLS) is an expansion of the company's r&d operations in the US and Europe and will support the company's pharmaceuticals business in both the innovator and generics markets.
The 20,000ft2 centre is in the Galen, in the Science Park III area of Singapore. When fully staffed, it is expected to house up to 70 r&d and operations personnel.
"Our expansion to Singapore is a significant part of our global development strategy," said Dr Alan Shaw, ceo of Codexis. "Singapore offers us access to a highly skilled workforce, proximity to our growing customer base in Asia, and a productive business environment as our company grows."
"We are pleased that Codexis has chosen to set up its research facility in Singapore," said S. Iswaran, Minister of State for Trade and Industry. "This investment is a strong endorsement for our ability to host such cutting-edge r&d activities, and will, no doubt, contribute to ensuring the long-term sustainability of our pharmaceutical manufacturing sector."